Back

Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy

Kungulovski, G.; Gjorgjievska, M.; Mehandziska, S.; Bukovec, D.; Risteski, M.; Kungulovski, I.; Mitrev, Z.

2024-10-16 genetic and genomic medicine
10.1101/2024.10.15.24315153 medRxiv
Show abstract

In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of thousands of tumor samples. Our analysis revealed that tumors with mutations in CRs are associated with high tumor mutational burden (TMB). The co-occurrence of mutations in multiple CRs was linked with a further increase in TMB. Given that TMB may predict the clinical response to immune checkpoint inhibitor (ICI) treatment, we investigated the relationship between mutations in CRs and ICI response. We found that patients harboring mutations in CRs exhibited improved responses to ICI treatment, comparable to those with deficiencies in canonical DNA repair pathways. Overall, this study uncovered significant relationships between mutations in chromatin regulators and critical features of cancer, underscoring the need for further functional and clinical studies.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 8%
11.7%
Similar papers in this journal
2
Nature Communications
○ 5641 papers in training set
Top 20%
8.8%
Similar papers in this journal
3
Genome Medicine
○ 183 papers in training set
Top 0.3%
7.2%
Similar papers in this journal
4
Cell Reports
○ 1498 papers in training set
Top 5%
6.6%
Similar papers in this journal
5
Nature Genetics
○ 286 papers in training set
Top 1%
5.4%
Similar papers in this journal
6
Cancers
○ 213 papers in training set
Top 1%
4.8%
7
EMBO Reports
○ 263 papers in training set
Top 0.9%
4.3%
8
Cell Genomics
○ 172 papers in training set
Top 1%
4.3%
50% of probability mass above
9
Cell Reports Medicine
○ 153 papers in training set
Top 0.7%
4.0%
10
Cancer Cell
○ 42 papers in training set
Top 0.4%
3.1%
11
iScience
○ 1154 papers in training set
Top 9%
2.7%
12
Cancer Research
● 130 papers in training set
Top 1%
2.6%
13
Cell
○ 431 papers in training set
Top 6%
1.7%
14
Cancer Research Communications
● 51 papers in training set
Top 0.9%
1.7%
15
Molecular Oncology
○ 55 papers in training set
Top 0.7%
1.7%
16
npj Precision Oncology
○ 53 papers in training set
Top 1%
1.5%
17
Life Science Alliance
● 285 papers in training set
Top 6%
1.1%
18
PLOS Genetics
● 862 papers in training set
Top 9%
1.1%
19
Communications Biology
○ 993 papers in training set
Top 26%
1.0%
20
Science Advances
● 1243 papers in training set
Top 28%
1.0%
21
Genome Research
● 468 papers in training set
Top 6%
0.8%
22
Journal of Hematology & Oncology
○ 10 papers in training set
Top 0.4%
0.8%
23
Frontiers in Oncology
○ 103 papers in training set
Top 3%
0.8%
24
Frontiers in Cell and Developmental Biology
○ 233 papers in training set
Top 6%
0.6%
25
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 1.0%
0.6%
26
Clinical and Translational Medicine
○ 31 papers in training set
Top 1%
0.6%
27
Scientific Reports
○ 3612 papers in training set
Top 78%
0.6%
28
Cell & Bioscience
○ 14 papers in training set
Top 0.2%
0.6%
29
EMBO Molecular Medicine
○ 95 papers in training set
Top 3%
0.6%
30
Nature Structural & Molecular Biology
236 papers in training set
Top 4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.